Regulatory update: Votrient® (pazopanib) as maintenance therapy for advanced ovarian cancer in the EU

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that it has withdrawn its application to the European Medicines Agency (EMA) for a variation to the Marketing Authorisation for Votrient® (pazopanib).
Source: GSK news - Category: Pharmaceuticals Source Type: news